Clinical efficacy of antiangiogenic therapy for diabetic macular edema in real clinical practice (2-year results)

Purpose:to evaluate the clinical efficacy of anti-VEGF therapy of patients with diabetic macular edema (DMO) in T & E regimen for 96 weeks. Materials and methods. The study included 59 patients (101 eyes) with DMO. The average number of intravitreal injections of anti-VEGF agent (IIAVA) — aflibercept given during the whole period was 12.87 ± 3.56, including 7.78 ± 1.20 in the first year, and 4.82 ± 2.66 in the second year. Results.All patients showed an increase in visual functions (+0.33, p < 0.001) with a maximum achieved after 5 injections (+0.24; p = 0.001). Central macular thickness decreased from 397.36 ± 100,00 μm at the initial level to 276.59 ± 52.90 after 5 loading injections (-120.8 μm), to 263.85 ± 45.20 (-133, 91 μm) after 1 year and to 248.6 ± 46.9 (-148.76 μm) after 2 years. A resorption of retinal neuroepithelial detachment was observed in 84.16 % of cases as soon as loading injections were given, and reached 100 % of cases by the 48th week of observation. Strong inverse correlations were revealed between the initial presence of medium and large intraretinal cysts and visual acuity, both initial and final (-0.35 and -0.42, p < 0.01). The disorganization of retina inner layers at the initial level was a predictor of a worse visual outcome at the end of the observation period. By the end of this period, 44 patients (43.5 %) received IIAVA with an interval of 12 weeks, the maximum interval between injections was 16 weeks and was achieved in 19 (28.01 %) eyes. Conclusion.The results of a 2-year retrospective study of the efficacy of aflibercept in DME showed that T&E regimen can be used with highfunctional results. Due to flexible planning of the number of IIAVA in the second year, over-treatment could be avoided without reducing the expected efficacy.

1. Schmidt-Erfurth U., Garcia-Arumi J., Bandello F., et al.Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017; 237 (4): 185–222. https://doi.org/10.1159/000458539

2. Ross E., Hutton D., Stein J., Bressler N., Jampol L., Glassman A. Costeffectiveness of Aflibercept, Bevacizumab, and Ranibizumab for diabetic macular edema treatment. JAMA Ophthalmol. 2016; 134 (8): 888. https://doi.org/10.1001/jamaophthalmol.2016.1669

3. Lipatov D., Lyshkanets O. Intravitreal therapy of diabetic macular edema in Russian Federation: current state of the problem. Vestnik oftal'mologii. 2019; 135 (4): 128–39.] https://doi.org/10.17116/oftalma2019135041128

4. Wells J., Glassman A., Ayala A., et al. Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema. Ophthalmology. 2016; 123 (6): 1351–9. doi.org/10.1016/j.ophtha.2016.02.022

5. Ohji M., Takahashi K., Okada A., Y., et al.Efficacy and safety of intravitreal Aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR. Adv. Ther. 2020; 37 (3): 1173–87. https://doi.org/10.1007/s12325-020-01236-x

6. Santoro E.Yu.Experience of using Aflibercept in diabetic macular edema treatment: data from routine clinical practice. Russian ophthalmological journal. 2018; 11 (4): 80–5 (in Russian)]. https://doi.org/10.21516/2072-0076-2018-11-4-80-85

7. Heier J., Korobelnik J., Brown D., et al. Intravitreal Aflibercept for diabetic macular edema. Ophthalmology. 2016; 123 (11): 2376–85. https://doi.org/10.1016/j.ophtha.2016.07.032

8. Brown D., Schmidt-Erfurth U., Do D., et al. Intravitreal Aflibercept for diabetic macular edema. Ophthalmology. 2015; 122 (10): 2044–52. https://doi.org/10.1016/j.ophtha.2015.06.017

9. Bressler S., Ayala A., Bressler N., et al. Persistent macular thickening after Ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016; 134 (3): 278. https://doi.org/10.1001/jamaophthalmol.2015.5346

10. Bressler N., Odia I., Maguire M., et al.Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to Aflibercept, Bevacizumab, or Ranibizumab. JAMA Ophthalmol. 2019; 137 (9): 977. https://doi.org/10.1001/jamaophthalmol.2019.1963

11. Zhang L., Wang W., Gao Y., Lan J., Xie L. The efficacy and safety of current treatments in diabetic macular edema: a systematic review and network metaanalysis. PLoS One. 2016; 11 (7): e0159553. https://doi.org/10.1371/journal.pone.0159553

12. Wykoff C., Ou W., Khurana R., et al. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. Br. Journ. Ophthalmol. 2017; 102 (5): 631–6. https://doi.org/10.1136/bjophthalmol-2017-310941

13. Vujosevic S., Bini S., Torresin T., et al. Hyperreflective retinal spots in normal and diabetic eyes. Retina. 2017; 37 (6): 1092–103. https://doi.org/10.1097/iae.0000000000001304

14. Antcliff R. Hydraulic conductivity of fixed retinal tissue after sequential excimer laser ablation. Archives of Ophthalmology. 2001; 119 (4): 539. doi.org/10.1001/archopht.119.4.539

15. Reznicek L., Cserhati S., Seidensticker F., et al.Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment. Acta Ophthalmol. 2013; 91 (7): e529-e536. https://doi.org/10.1111/aos.12153

16. Murakami T., Nishijima K., Akagi T., et al. Optical Coherence Tomographic reflectivity of photoreceptors beneath cystoid spaces in diabetic macular edema. Invest. Opthalmol. Vis. Sci. 2012; 53 (3): 1506. https://doi.org/10.1167/iovs.11-9231

17. Sun J., Radwan S., Soliman A., et al. Neural retinal disorganization as a robust marker of visual acuity in current and resolved diabetic macular edema. Diabetes. 2015; 64 (7): 2560–70. https://doi.org/10.2337/db14-0782

18. Radwan S., Soliman A., Tokarev J., et al. Association of disorganization of retinal inner layers with vision after resolution of center-involved diabetic macular edema. JAMA Ophthalmol. 2015; 133 (7): 820. https://doi.org/10.1001/jamaophthalmol.2015.0972

19. Joltikov K., Sesi C., de Castro V., et al.Disorganization of retinal inner layers (DRIL) and neuroretinal dysfunction in early diabetic retinopathy. Invest. Opthalmol. Vis. Sci. 2018; 59 (13): 5481. https://doi.org/10.1167/iovs.18-24955

20. Mori Y., Suzuma K., Uji A., et al.Restoration of foveal photoreceptors after intravitreal ranibizumab injections for diabetic macular edema. Sci. Rep. 2016; 6 (1). https://doi.org/10.1038/srep39161

21. Fursova A., Chubar’ N., Tarasov M., Sayfullina I., Pustovaya G.Clinical associations between photoreceptor status and visual outcomes in diabetic macular edema. Vestnik oftal'mologii. 2017; 133 (1): 11–8]. https://doi.org/10.17116/oftalma2017133111-18